Et al Phillip Frost MD - 28 Oct 2025 Form 4 Insider Report for Cocrystal Pharma, Inc. (COCP)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: COCP
Reported as of: 28 Oct 2025
Net transaction value: +$1,500,003
SEC form: 4
Accepted by SEC: 30 Oct 2025, 16:15:25 UTC
Prior SEC filing: 15 Sep 2025
Next SEC filing: 31 Oct 2025
Source filing: View source filing
Reporting owner signature: /s/ Phillip Frost, MD ET AL

Key filing fact

Et al Phillip Frost MD filed Form 4 for Cocrystal Pharma, Inc. (COCP) on 30 Oct 2025.

Key facts

This page summarizes Et al Phillip Frost MD's Form 4 filing for Cocrystal Pharma, Inc. (COCP).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 30 Oct 2025, 16:15.

Change

Previous filing in this sequence was filed on 15 Sep 2025.
Current net transaction value: +$1,500,003.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0000898860 Primary reporting owner

FROST PHILLIP MD ET AL

Relationship: Director, 10%+ Owner
Address: 4400 BISCAYNE BLVD, MIAMI
Signature: /s/ Phillip Frost, MD ET AL
Signature date: 30 Oct 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

COCP transaction

Common Stock

Award

Transaction value: $500,001
Shares: +359,713
Change %: +27%
Price: $1.39
Shares after: 1,679,551
Date: 28 Oct 2025
Ownership: By Frost Gamma Investments Trust
Footnotes: F1, F2

COCP holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 27,100
Date: 28 Oct 2025
Ownership: Direct
Footnotes: F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

COCP transaction Derivative

Warrants

Award

Transaction value: $1,000,002
Shares: +719,426
Change %
Price: $1.39
Shares after: 719,426
Date: 28 Oct 2025
Ownership: By Frost Gamma Investments Trust
Underlying class: Common Stock
Underlying amount: 719,426
Exercise price: $1.24
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The Reporting Person purchased units at $1.39 per unit with each unit consisting of one share of common stock and a warrant to purchase two shares of common stock. The shares of common stock and warrants purchased are exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 thereunder, as it was approved by a Special Committee of the Board of Directors of the Issuer, which Special Committee consisted of two non-employee directors. The warrants were exercisable upon issuance.

Footnote F2

These shares are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole stockholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is the sole stockholder of Frost-Nevada Corporation. The Reporting Person disclaims beneficial ownership of the securities held by Frost Gamma Investments Trust except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Footnote F3

Includes shares of common stock issuable upon vesting of restricted stock units.

SEC remarks

This Form 4 does not include any of the securities owned directly by OPKO Health, Inc., a company of which Dr. Frost is the Chairman of the Board and Chief Executive Officer, concerning the securities of which Dr. Frost does not hold voting and investment control. Dr. Frost disclaims beneficial ownership of the securities held by OPKO Health, Inc. except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that Dr. Frost is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.